Early-Stage Pulmonary Arterial Hypertension Therapy From Pulmokine Awarded $1.5 Million Through Federally Funded VITA Contract

Rensselaer, New York-based biopharmaceutical company Pulmokine recently made a major announcement regarding the company’s efforts in developing a novel therapy for pulmonary arterial hypertension (PAH). In a press release from late March, Pulmokine indicated that that the National Heart, Lung, and Blood Institute (NHLBI), a division of the federally run National…

A Conversation With Rare Disease Advocates